ArticleSmart molecules : open access2026
A lysosome-targeted ultra-sensitive viscosity probe for monitoring viscosity alterations during chemotherapy.
Article in Smart molecules : open access, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lysosomal viscosity is a key biomarker of cancer progression and chemotherapy response, but real-time, precise monitoring remains challenging. To address this challenge, we develop a novel chemosensing platform based on a molecular rotor architecture for specific, dynamic detection of lysosomal viscosity. The platform operates via an "off-on" switching mechanism: in low-viscosity environments, rapid rotor rotation through the twisted intramolecular charge transfer effect quenches fluorescence; in high-viscosity conditions, restricted rotation triggers strong emission, enabling an ultra-sensitive and selective response. Using systematic molecular engineering and screening within this platform, the probe PMA-H is identified as the optimal candidate, demonstrating a remarkable 187-fold fluorescence enhancement in response to viscosity (from 0.54 to 1410 cP), excellent environmental stability with minimal interference from pH, polarity, or biomolecules, and precise lysosomal targeting. Subsequently, PMA-H is employed to track lysosomes in HeLa cells, and it reveals alterations in lysosomal viscosity, morphology, and abundance during apoptosis, ferroptosis, cuproptosis, and zinc-induced cell death. In general, this platform allows real-time tracking of lysosomal viscosity fluctuations induced by various chemotherapeutic agents, highlighting its significant potential as a powerful tool for early cancer diagnostics and fundamental lysosomal research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.